What are the indications for Everolimus (Afinitor)? Which patients are suitable for this drug?

Everolimus is an oral mTOR inhibitor that inhibits cell proliferation, angiogenesis and tumor growth by blocking the mammalian target of rapamycin (mTOR) signaling pathway. The drug has significant efficacy in a variety of clinical fields, including tumor treatment and organ transplantation immunosuppression. It is an important type of targeted drug.

The indications of everolimus in the oncology field include: patients with advanced renal cell carcinoma (RCC), for first-line or maintenance treatment after failure of previous treatment; patients with hepatocellular carcinoma and neuroendocrine tumors (NET), for controlling tumor progression; and children and adults with tuberous sclerosis associated with kidney, brain or lung lesions. In addition, it can also be used in the adjuvant treatment of certain breast cancer and pancreatic neuroendocrine tumors.

In the field of organ transplantation, everolimus is suitable for kidney transplant, liver transplant or heart transplant patients to prevent transplant organ rejection. Particularly suitable for patients who are intolerant to traditional calcineurin inhibitors or have impaired renal function. By regulating immune system activity, everolimus can reduce the incidence of rejection and reduce some drug-related toxicities.

Patients who are suitable for the use of everolimus need to evaluate the type of disease, severity of illness and previous medication history under the guidance of a doctor. During use, hematological indicators, liver and kidney function, blood sugar, and blood lipid levels need to be monitored regularly to prevent infection, stomatitis, metabolic abnormalities and other adverse reactions. Elderly patients, those with liver and kidney dysfunction, or those with multiple chronic diseases should adjust the dose individually to ensure both efficacy and safety of the drug.

Reference materials:https://www.drugs.com/